Liquid Biopsy in High-grade Gliomas and Meningiomas

Launched by IRCCS SAN RAFFAELE · Nov 24, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how certain DNA markers found in the blood can help doctors understand the progression of high-grade gliomas and meningiomas, which are types of brain tumors. Researchers want to see if changes in these DNA markers, taken from blood samples at different times—before and after surgery, after radiation therapy, and when the tumor appears to grow again—can give clues about how well a patient is doing and how their body is responding to treatment.

To participate in this trial, individuals need to be at least 18 years old and have a brain tumor that is suspected to be high-grade based on an MRI scan. They should also be able to have surgery to remove or biopsy the tumor. The trial is open to all genders, and participants will need to sign a consent form. Importantly, those with certain medical conditions or who are pregnant or breastfeeding cannot join. Throughout the trial, participants will provide blood samples at four key points, helping researchers gather valuable information about their health and treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Finding, on an MRI scan of the brain with gadolinium, of a brain lesion compatible with a primary brain tumor, intra- or extra-axial, suspected for a high-grade glioma or a high-grade meningioma, manifested with new onset neurological symptoms
• • Clinical indication to perform a biopsy or surgical resection of the lesion
• • Karnofsky Performance Status (KPS) ≥ 60
• • Signature of informed consent
• Exclusion Criteria:
• • Absolute contraindications to magnetic resonance imaging or to the administration of gadolinium (e.g. patients with pacemakers or other non-magneto-compatible devices)
• • Known positivity for HIV, HCV or HBV
• • There are clinical, biological or instrumental data suggesting that the brain lesion is non-neoplastic in nature (e.g., abscess, vascular malformation, inflammatory disease of the Central Nervous System)
• • Women who are pregnant or breastfeeding